CONFIDENTIAL-S1
filed
Confidential registration lead
Sensorion announced on September 16, 2026 that it confidentially submitted a draft Form F-1 to the SEC as a preliminary step in evaluating a potential U.S. IPO of ordinary shares, including ADSs. The ADSs would be listed on an unspecified U.S. national exchange, subject to market and other conditions. No U.S. ticker, offer size, price or timing was disclosed.
Ordinary shares, including in the form of American Depositary Shares · Flags adr, foreign_private_issuer
French biotechnology issuer Sensorion confirmed a confidential Form F-1 submission on September 16 to evaluate a potential U.S. IPO, potentially using ADSs. This is an early-stage filing signal without disclosed cover terms, syndicate, exchange, ticker or timetable.
2026-09-16 · CONFIDENTIAL-42D90D2B93BA2FB6EDEC